Transgene : TG4001 did not achieve its phase II primary endpoint
>Failure of TG4001 - We learned this morning that the first results of the phase II trial evaluating TG4001 in combination with Merck’s Bavencio did not achieve its primary endpoint in patients with recurrent or metastatic HP16-positive cervical and anogenital tumours (caused by the papillomavirus). At this stage we have no details on these results or the data. We can underline two aspects: it appears that a sub-group of patients showed a positive “trend” in term...Transgene is a biopharmaceutical company that designs and develops immunotherapy and virotherapy products for the treatment of cancers and infectious diseases. Co. is developing three anti-cancer products that are in clinical trials: (cancer of the lungs, liver and oropharynx); two anti-infectious immunotherapy products also in clinical trials: (hepatitis B and C). Co. also has products in the pre-clinical development stage. Co. operates in a single business segment, the research and development of therapeutic vaccines and immunotherapy products. Co. does not have any products on the market. Substantially all of its operations are conducted in France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.